ERBB2 and breast cancer: Molecular subtyping of BC is now based on classical immunohistochemistry markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) that led to the distinction between luminal (A and B), basal, and HER2-positive classes [1, 2].